AI startup Paige launched an AI-powered biomarker module that the company says can evaluate more than 505 genes and identify 1,228 molecular biomarkers from standard pathology slides.
Solving three major challenges in the development of new oncology drugs
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
More precise and consumer-friendly biomarker detection technologies are coming to market at a pace that can help users gain rich insight into their health and well-being from anywhere and at any time. This is especially important when it comes to preventive healthcare.
Innovation hub and startup engagement models in the life sciences can take one of a few flavors with equity investments, commercial partnerships and accelerator programs covering most of the cases.
Startups are turning to voice data as they try to develop tools to detect a wide range of diseases. One startup, Vocalis Health, is working with Mayo Clinic to identify voice-based biomarkers for pulmonary hypertension.
Alphabet’s “moonshot” subsidiary X shared that it failed to find a single biomarker for depression and anxiety. But the company still plans to make its research, which included developing portable EEGs, available to the public.
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
The company, which was founded in 2014 by a team including genetics pioneer Leroy Hood, raised more than $50 million over its existence from investors including Maveron, Polaris Partners and ARCH Venture Partners.
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.